Exploring VISTA Levels in Patients with Vascular Cognitive Impairment
Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment
This study is testing how levels of a protein called VISTA in the blood and spinal fluid relate to cognitive problems in people with heart and blood vessel issues over several years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Harbin Medical University Academic / other |
| Locations | 1 site (Harbin, Heilongjiang) |
| Trial ID | NCT06342661 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the expression levels of the immune checkpoint VISTA in the blood and cerebrospinal fluid of patients with cardiovascular risk factors. It aims to correlate these levels with various risk factors such as hypertension and diabetes, as well as immune-inflammatory factors like IL1 and TNFα. The study includes a follow-up of patients over 3 to 5 years to track changes in VISTA levels and their relationship with cognitive impairment. The research is conducted at the First Hospital of Harbin Medical University.
Who should consider this trial
Good fit: Ideal candidates include individuals with vascular cognitive impairment and those without cognitive impairment but with cardiovascular risk factors.
Not a fit: Patients with autoimmune diseases, blood disorders, or recent acute inflammatory diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the role of VISTA in vascular cognitive impairment, potentially leading to new therapeutic strategies.
How similar studies have performed: While studies on immune checkpoints in neurological conditions exist, this specific focus on VISTA in vascular cognitive impairment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The study included 100 subjects, including 50 patients with VCI and 50 normal controls. The diagnosis of VCI was based on the diagnostic criteria for psychiatric disorders in the fifth revised edition of the "Diagnostic and Statistical Manual of Mental Disorders" of the American Psychiatric Association; 2. All relevant examination and cognitive testing work in this study obtained informed consent from the subjects and their families. Exclusion Criteria: 1\. In line with the exclusion criteria for VCI diagnosis in the "Chinese guidelines for the treatment of vascular cognitive impairment 2019"; complicated with autoimmune diseases, blood diseases, malignant tumors, heart, liver, and kidney dysfunction, infectious diseases, family genetic diseases, recent acute or chronic inflammatory diseases, myocardial infarction, etc.; taking antibiotics, steroids, immunosuppressants before the trial; having a history of cranial trauma or surgery.
Where this trial is running
Harbin, Heilongjiang
- First Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang, China (Recruiting)
Study contacts
- Study coordinator: Dan Liu
- Email: liudan19911214@126.com
- Phone: 15145086350
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.